Aurobindo has agreed to sell its US-based Natrol dietary supplements business at a significant premium to the $132.5m it paid in late 2014, as the Indian firm continues to drive into complex formulations in the US, including injectables and biosimilars.
Aurobindo has pledged to pay down debt and invest in “new strategic initiatives,” after agreeing to divest the company’s US-based Natrol dietary supplements business for approximately $550m in cash.
The transaction, offloading Natrol to an affiliate of US-based private equity New Mountain Capital, is scheduled to close to close...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
